CHST14 Protein - Dermatan 4-O-Sulfotransferase 1
Overview
CHST14 (carbohydrate sulfotransferase 14) is a membrane-bound enzyme that catalyzes the sulfation of dermatan sulfate, a glycosaminoglycan abundant in the extracellular matrix. Also known as dermatan 4-O-sulfotransferase 1 (D4ST1), this protein is encoded by the CHST14 gene located on chromosome 8q24.22. CHST14 catalyzes the transfer of a sulfate group from 3'-phosphoadenosine 5'-phosphosulfate (PAPS) to the C-4 position of the N-acetylgalactosamine residues in dermatan sulfate chains. This post-synthesis modification is critical for establishing the structural and functional properties of dermatan sulfate in connective tissues and the nervous system.
Function and Biology
CHST14 operates as a sulfotransferase within the Golgi apparatus and early secretory pathway, where it modifies glycosaminoglycans during their biosynthesis. The enzyme utilizes PAPS as the activated sulfate donor, catalyzing the sulfation reaction with high specificity for dermatan sulfate containing β1-3-linked galactosamine residues. This modification directly affects the charge density, three-dimensional conformation, and binding properties of dermatan sulfate molecules.
...CHST14 Protein - Dermatan 4-O-Sulfotransferase 1
Overview
CHST14 (carbohydrate sulfotransferase 14) is a membrane-bound enzyme that catalyzes the sulfation of dermatan sulfate, a glycosaminoglycan abundant in the extracellular matrix. Also known as dermatan 4-O-sulfotransferase 1 (D4ST1), this protein is encoded by the CHST14 gene located on chromosome 8q24.22. CHST14 catalyzes the transfer of a sulfate group from 3'-phosphoadenosine 5'-phosphosulfate (PAPS) to the C-4 position of the N-acetylgalactosamine residues in dermatan sulfate chains. This post-synthesis modification is critical for establishing the structural and functional properties of dermatan sulfate in connective tissues and the nervous system.
Function and Biology
CHST14 operates as a sulfotransferase within the Golgi apparatus and early secretory pathway, where it modifies glycosaminoglycans during their biosynthesis. The enzyme utilizes PAPS as the activated sulfate donor, catalyzing the sulfation reaction with high specificity for dermatan sulfate containing β1-3-linked galactosamine residues. This modification directly affects the charge density, three-dimensional conformation, and binding properties of dermatan sulfate molecules.
Dermatan sulfate, modified by CHST14, plays essential roles in extracellular matrix organization, protein-ligand interactions, and cell signaling. The sulfation patterns generated by CHST14 enhance binding affinity for various protein ligands including growth factors, cytokines, and adhesion molecules. These interactions influence cell adhesion, migration, differentiation, and tissue remodeling processes. In the nervous system specifically, dermatan sulfate modifications regulate neuronal development, synaptic plasticity, and axonal regeneration through interactions with neurotrophic factors and cell surface receptors.
Role in Neurodegeneration
Emerging evidence suggests that CHST14 dysfunction contributes to multiple neurodegenerative conditions. Abnormalities in glycosaminoglycan sulfation patterns, including dermatan sulfate defects, have been observed in Alzheimer's disease, where altered sulfation correlates with amyloid-beta accumulation and tau pathology. The impaired extracellular matrix environment resulting from reduced CHST14 activity compromises neuroinflammatory regulation and amyloid clearance mechanisms.
In Parkinson's disease and Lewy body dementias, altered dermatan sulfate sulfation affects alpha-synuclein aggregation and clearance. The extracellular matrix modifications influenced by CHST14 regulate proteolytic processing and aggregate deposition of pathological proteins. Additionally, Huntington's disease research indicates that sulfation defects impair neuroprotective signaling through growth factor pathways, particularly brain-derived neurotrophic factor (BDNF) signaling, which is compromised by aberrant glycosaminoglycan modifications.
Molecular Mechanisms
CHST14 mutations and downregulation disrupt the balance of positively and negatively charged domains within the extracellular matrix. This alters the recruitment and sequestration of soluble proteins and modulates the bioavailability of neurotrophic factors. Reduced sulfation decreases the matrix's capacity to bind and retain factors like nerve growth factor (NGF), fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF), compromising neuroprotective signaling cascades.
Furthermore, aberrant dermatan sulfate sulfation patterns promote neuroinflammatory activation through altered interaction with toll-like receptors and other pattern recognition receptors. This dysregulated innate immune response accelerates microglial activation and pro-inflammatory cytokine production, exacerbating neurodegeneration. The modified extracellular matrix also affects blood-brain barrier integrity and clearance of misfolded protein aggregates through glymphatic system dysfunction.
Clinical and Research Significance
Mutations in CHST14 cause d4st1-deficient progeroid syndrome, an inherited connective tissue disorder with secondary neurological manifestations including progressive cognitive decline and neurological dysfunction. This genetic model provides crucial insights into the contribution of glycosaminoglycan dysregulation to neurodegeneration. Therapeutic targeting of CHST14 activity or dermatan sulfate composition represents a potential strategy to enhance neuroprotection through extracellular matrix stabilization and improved neurotrophic factor signaling.
- Dermatan Sulfate - glycosaminoglycan substrate
- Glycosaminoglycans - broader family of molecules
- PAPS - sulfate donor molecule
- Extracellular Matrix - primary location of CHST14 substrates
- Neuroinflammation - downstream process affected by CHST14 dysfunction
- Neurotrophic Factors - proteins regulated by CHST14-modified matrix